[对谢翔通新药药丸的临床综合评估]
1International Research Center for Medicinal Administration, Peking University Beijing 100191, China.
概括
谢祥通滴剂是有效和安全的治疗冠状动脉心脏病与奇缺乏和血液静止. 这种传统中医药具有显著的临床价值和药物经济优势.
科学领域:
- 传统中国医药 传统中国医药
- 药理学 药理学是指药理学的学科.
- 基于证据的医学基于证据的医学.
背景情况:
- 冠状动脉心脏病 (CHD) 伴随着 Qi 缺乏和血液静止,是一个重大的临床挑战.
- 传统中医 (TCM) 为管理稳定性心痛提供了潜在的治疗选择.
研究的目的:
- 综合评估谢祥通脱药 (STDP) 治疗稳定性心痛的临床价值.
- 以安全性,有效性,经济性,创新性,适用性和可访问性为基础评估STDP,使用多标准决策分析 (MCDA) 模型.
主要方法:
- 文学和问卷调查,以收集关于STDP的证据.
- 应用多标准决策分析 (MCDA) 模型进行综合评估.
- 质量控制 遵守基于证据的医学原则.
主要成果:
- 推使用STDP治疗心脏病的稳定性 angina,治疗有 Qi 缺乏和血静止的心脏病.
- 有效性 (A级):减少心痛的频率和持续时间,改善运动耐受性和生活质量.
- 安全性 (A级):通常是轻微的不良反应,与已知的风险一致.
- 经济绩效 (A级):具有成本效益,每日成本为7.74元.
- 创新 (A级):表现出良好的临床和服务创新.
- 适用性 (A级):符合药物指南规格,没有特殊限制.
- 可访问性 (A级):一般来说,价格,可用性和负担能力都很好.
结论:
- 谢翔通滴剂在冠状动脉心脏病中对稳定性心痛有很大的临床价值.
- 综合评估证实了STDP在安全性,有效性,经济性,创新性,适用性和可访问性方面的高评级.
相关概念视频
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Clearance: Overview
Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including the...
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including the...
Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...


